globenewswire

5. juunil 2025 võttis Arco Vara ASi aktsionäride korraline üldkoosolek vastu otsuse viia läbi suunatud aktsiaemissioon kindlatele investoritele eesmärgiga suurendada ettevõtte aktsiakapitali.
Arco Vara AS teatab, et aktsionäride poolt heaks kiidetud suunatud aktsiaemissioon on edukalt lõpetatud 11. juunil 2025 – juhatus on võtnud vastu otsuse märkimisperioodi lühendamiseks seoses välja lastud aktsiate ennetähtaegse märkimisega. Vastavalt vastu võetud üldkoosoleku otsusele:

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax¹

빅토리아, 세이셸, June 12, 2025 (GLOBE NEWSWIRE) -- 암호화폐 거래소이자 웹3.0 선도기업인 Bitget이 사용자 보안 펀드인 보호 펀드 (Protection Fund)가 5월에 7억 2,510만 달러로 최고치를 기록하며 설립 이래 최고 수치를 달성하게 되었다고 2025년 5월 보고서를 발표했다. 극심한 시장 상황에서 사용자 자산을 보호하기 위해 설계된 이 펀드는 한 달 내내 꾸준한 성장세를 보이며 월 평균 6억 7,350만 달러의 가치를 기록했다.

Utrecht, 12 June 2025

Leuven, Belgium, June 12, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the appointment of Dieter Weinand as Chair of the Board of Directors, effective June 12, 2025. Mr. Weinand is the former Chief Executive Officer of Bayer Pharma AG with more than 25 years of experience as a senior business leader in the pharmaceutical industry. He takes over from Dr. Jeanne Bolger, who served as Chair since 2022 and will remain on the Board as a non-executive independent director.

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.

SIKA IS UNLOCKING SMART AND DURABLE SOLUTIONS FOR DATA CENTER CONSTRUCTION

Today in Dallas, United States, Sika outlines strategic initiatives and high-performance solutions that will drive the future of data center construction. With over 1,000 data centers built using Sika solutions and a strong pipeline of new projects, Sika has become the trusted partner of technology leaders shaping digital infrastructure worldwide.

New feature eliminates manual setup, enhances security, and simplifies bulk device enrollment for businesses

WEST VALLEY CITY, Utah, June 11, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming radioisotope production and enabling next-generation energy solutions, announced today the launch of a High-Assay Low-Enriched Uranium (HALEU) production program to support the need for new, sustainable energy solutions and small modular nuclear reactor (SMR) infrastructure in the United States.